Sk Chemicals Co., Ltd.

Daewoong Pharmaceutical Co., Ltd.

Tiumbio Co., Ltd.

Fairchild Korea Semiconductor Ltd.

Ewha University-Industry Collaboration Foundation

Sk Bioscience Co., Ltd.

Bong-Yong Lee

Jae-Sun Kim

Hun-Taek Kim

Keun-Ho Ryu

Jung-Hoon Oh

Ju Young Lee

Soo-Min Lee

Sooheun Lee

Ji-Hye Lee

Hyun Jung Lee

Jaeseung Ahn

Won-No Youn

Joon-Gyo Oh

Shin Hyoung Kim

So-young Lee

Bo Ram Lee

Je Ho Ryu

Yeo-Jin Park

Mahn-Hoon Park

In-Young Song

Hyun-Jung Lee

Yun-Hee Kim

Nam Ho Kim

Dong Chul Shin

Keun Ryu

Young-chul Choi

Kyu Ho Lee

Sung Hoon Park

Hoe Chul Jung

Jung A Lee

Ye-Ji Jeon

Sung-hoon Park

Seon-Mi Kim

Kyu-hyun Lee

Jung Bum Yi

Hun Kee Kim

Hee-kyoon Yoon

Jeong-Taek Shin

Hong Kee Kim

Kyeong-seok Park

Jae Sun Kim

Sang-hwan Kang

Yun Jung Lim

Euisun Park

Young Ah Shin

Jong-Seob Im

Seo Yeon Son

Min-Sun Kim

Ho-Soon Lee

Yong-Hyuk Kim

Wol-Young Kim

Min-Young Han

Yong Youn Hwang

Won-Jae Choi

Young-Ah Shin

Young-chul Kim

Yoon-Jung Lee

Taekyung Yoo

Hyun Joo Son

Joon Ho Sa

Yong-Youn Hwang

Minhee Lee

Dong-Chul Shin

DongChul Shin

Hyung-Geun Lee

Hong Kee Sah

Key-An Um

Myung-gi Jung

Yong Hyuk Kim

Yunju Oh

Min Sun Lee

Shin Ae Kim

Hye-Min Kim

Mahn Hoon Park

Min-Jae Cho

Mahnhoon Park

Su-Jeen Lee

Hye Young Han

Hae-In Rhee

Hoechul Jung

Hoe-chul Jung

Sang-Hwan Kang

So-Young Lee

Myung-Gi Jung

Hong-Kee Kim

Seok Hyun Hong

Keun Ho Ryu

The present invention relates to a heterocyclic compound represented by Chemical Formula 1 that can be used for the prevention or treatment of diseases caused by abnormality in a PRS (prolyl-tRNA synthetase) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.

Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same

A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.

Fusion protein having factor VII activity

The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-&#x3b2; (TGF-&#x3b2;) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

The present invention provides a process for preparing an ertapenem-containing lyophilized formulation, comprising the use of hydroxypropyl &#x3b2;-cyclodextrin as both a cryoprotective agent and a stabilizing agent.

Process for preparing ertapenem-containing lyophilized formulation

Provided are a power device having an improved field stop layer and a method of manufacturing the same. The power device includes: a first field stop layer formed of a semiconductor substrate and of a first conductive type; a second field stop layer formed on the first field stop layer and of the first conductive type, the second field stop layer having a region with an impurity concentration higher than the first field stop layer; a drift region formed on the second field stop layer and of the first conductive type, the drift region having an impurity concentration lower than the first field stop layer; a plurality of power device cells formed on the drift region; and a collector region formed below the first field stop layer, wherein the second field stop layer includes a first region having a first impurity concentration and a second region having a second impurity concentration higher than the first impurity concentration.

Power device including a field stop layer

Provided is a transdermal delivery system (for example, in the form of a patch) having a double-layer structure including a drug-containing matrix layer and an adhesive layer, wherein the drug-containing matrix layer is obtained by completely dissolving donepezil using a certain polymer and then formulating along with an adhesive; and a process for preparing the same. The transdermal delivery system according to the present invention does not show any crystallization of donepezil in the formulation, can release donepezil at a uniform rate for a long time, and can inhibit the release dumping phenomenon that occurs in a transdermal delivery system having a single-layer structure.

Percutaneous absorption preparation containing donepezil, and method for preparing same

Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.

Fusion protein having factor IX activity

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

Disclosed is a Madin-Darby canine kidney (MDCK)-derived cell line. The MDCK-derived cell line is derived from MDCK cells deposited under accession number ATCC CCL-34. The MDCK-derived cell line can be prepared by serum-free culture and suspension culture. Preferably, the MDCK-derived cell line has low or no tumorigenicity. The MDCK-derived cell line is preferably selected from MDCK Sky1023, MDCK Sky10234 and MDCK Sky3851. Further disclosed are a culture method for growing the MDCK-derived cells and a method for producing a vaccine virus using the MDCK-derived cells.

MDCK-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells

Disclosed is a composition effective in reducing skin wrinkles. The composition comprises a phosphodiesterase 5 (PDE5) inhibitor, preferably the compound of chemical formula 1, more preferably, mirodenafil as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.

Composition for reducing skin wrinkles including PDE5 inhibitor

The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin F2&#x3b1; analogs.

Composition for eyelash growth

Disclosed is a composition effective in reducing skin wrinkles. The composition comprises or uses a phosphodiesterase 5 (PDE5) inhibitor as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11&#x3b2;-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11&#x3b2;-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11&#x3b2;-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same

Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.

Composition with improved skin penetration for transdermal delivery of tolterodine

Growing community of inventors

Seoul, South Korea

Bong-Yong Lee